© Globe Newswire
15.01.2025
ORNBV
LISTED
HEL
Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2025 Annual General Meeting
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE15 JANUARY 2025 at 10.45 EET ...
Themefolio
Profiler
Peergroup
© EQS Newswire
15.01.2025
FYB
LISTED
XETR
Formycon und Fresenius Kabi geben die Zulassung von FYB202/Otulfi® (ustekinumab), einem Biosimilar zu Stelara®, durch die britische MHRA bekannt
News Preview
Pressemitteilung // 15. Januar 2025
Formycon und Fresenius Kabi geben die Zulassung von FYB202/Otulfi® (ustekinumab), einem Biosimilar zu Stelara®, durch die britische MHRA bekannt
Otulfi® hat die MHRA-Zulassung für subkutane und intravenöse Formulierungen zur Behandlung schwerer entzündlicher Erkrankungen erhalten
Die Zulassung im Vereinigten K......
Themefolio
Profiler
Peergroup
© EQS Newswire
15.01.2025
FYB
LISTED
XETR
Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
News Preview
Press Release // January 15, 2025
Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
Otulfi®received MHRA approval for both subcutaneous and intravenous formulations, to treat serious inflammatory diseases
UK approval follows the series of successful approvals by the FDA, the European Co......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© ActuNews
14.01.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities LLC
News Preview
Leuven, BELGIUM – January 14, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received an amended transparency notification as follows:
Oxurion received a transparency notification on January 13, 20...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ActuNews
14.01.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt aangepaste transparantiekennisgeving van Atlas Special Opportunities LLC
News Preview
Leuven, BELGIË – 14 januari 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende aangepaste transparantiekennisgeving heeft ontvangen:
Oxurion ontving ee...
Themefolio
Profiler
Peergroup
© EQS Newswire
14.01.2025
EUZ
LISTED
XETR
Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture
News Preview
Berlin, 14 January 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a licence agreement with Qi Kang Medical, Ltd (QKM), a joint venture between Eckert & Ziegler and the Chinese company DC Pharma, for the cyclotron technology used by Eckert & Ziegler to manufacture Ac-225. The contract guarantees Eckert & Ziegler a......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.01.2025
EUZ
LISTED
XETR
Eckert & Ziegler schließt Lizenzvertrag für Actinium-225 mit chinesischem Joint Venture
News Preview
Berlin, 14. Januar 2025. Die Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) hat heute mit Qi Kang Medical, Ltd (QKM), einem Joint-Venture der Eckert & Ziegler und der chinesischen DC Pharma, einen Lizenzvertrag über die von Eckert & Ziegler verwendete Zyklotron-Technologie zur Herstellung von Ac-225 unterzeichnet. Der Vertrag sichert E......
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2025
CYRX
LISTED
NASDAQ
Moffitt Cancer Center and Cryoport Announce Strategic Collaboration
News Preview
Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services
TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 /PRNewswire/ -- Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL, a 775-acre global innovation life sciences campus, a...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2025
TEM
LISTED
NASDAQ
Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative capabilities available in Tempus One, the company’s generative AI assistant. Tempus One, which initially launched in 2023, provides both physicians and researchers AI-enabled...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2025
ICLR
LISTED
NASDAQ
ICON Issues Financial Guidance for Full Year 2025
News Preview
ICON plc, (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2025. For the full year 2025, revenue is expected to be in the range of $8,050 - $8,650 million, representing growth of approximately 1% at the midpoint and adjusted ea...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2025
HIK
LISTED
LSE
Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg
News Preview
LONDON, Jan. 14, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announces that it has entered an exclusive commercial partnership with Emergent BioSolutions (Emergent) for the sale of KLOXXADO® naloxone HCl nasal spray 8 mg in the U.S. and Canada. KLOXXADO® was approved by the US Food and Dru...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2025
SN
LISTED
LSE
Smith+Nephew’s ALLEVYN™ LIFE Sacrum Foam Dressing and LEAF™ Patient Monitoring System receive ‘favorable’ Evidence Bar™ ratings from ECRI for pressure injury prevention
News Preview
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that ECRI – leaders in advancing evidence-based healthcare globally - have completed updated Clinical Evidence Assessments of ALLEVYN LIFE Sacrum Foam Dressings and the LEAF Patient Monitoring System. In their latest reports, ECRI upgraded its Evidence Bar ratin...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
14.01.2025
TIL
LISTED
NASDAQ
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
News Preview
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2025
BIOA B
LISTED
STO
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
News Preview
STOCKHOLM, Jan. 14, 2025 /PRNewswire/ --BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosingLeqembi is indicated for the treatment of Al...
Themefolio
Profiler
Peergroup
© PR Newswire
14.01.2025
BIOA B
LISTED
STO
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
News Preview
STOCKHOLM, Jan. 13, 2025 /PRNewswire/ --BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosingLeqembi is indicated for the treatment of Al...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
GNFT
LISTED
EURONEXT
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
News Preview
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 13 janvier 2025 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui le bilan semestriel du contra...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
DBV
LISTED
EURONEXT
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
News Preview
AMF Regulated InformationChâtillon, France, January 13, 2025...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.01.2025
SOON
LISTED
SIX
Sonova to present at the J.P. Morgan 2025 Healthcare Conference
News Preview
Sonova Holding AG
/ Key word(s): Conference
Sonova to present at the J.P. Morgan 2025 Healthcare Conference
13.01.2025 / 18:00 CET/CEST
Group Media & Investor Release
Staefa (Switzerland), January 13, 2025 – Sonova Holding AG (SWX: SOON), a leading provider of innovative hearing solutions, announces that its Chief E......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.01.2025
SOON
LISTED
SIX
Sonova präsentiert auf der J.P. Morgan 2025 Healthcare Conference
News Preview
Sonova Holding AG
/ Schlagwort(e): Konferenz
Sonova präsentiert auf der J.P. Morgan 2025 Healthcare Conference
13.01.2025 / 18:00 CET/CEST
Group Media & Investor Release
Staefa (Schweiz), 13. Januar 2025 – Sonova Holding AG (SWX: SOON), ein führender Anbieter innovativer Hörlösungen, gibt bekannt, dass CEO Arnd Kald......
Themefolio
Profiler
Peergroup
© ActuNews
13.01.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC
News Preview
Leuven, BELGIË – 13 januari 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transpara...
Themefolio
Profiler
Peergroup
© ActuNews
13.01.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
News Preview
Leuven, BELGIUM – January 13, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on January 13, 2025, from...
Themefolio
Profiler
Peergroup
© ActuNews
13.01.2025
OXUR
LISTED
EURONEXT
OXURION : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
News Preview
Atlas Special Opportunities, LLC heeft 4 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 100.000. Deze conversie vormt deel van Atlas Special Opportunities, LLC's EUR 20 miljoen kapitaaltoezegging1 die aan Oxurion zal toelaten om te focussen op het ontwikkelen van innovatieve geneesmiddelen om he...
Themefolio
Profiler
Peergroup
© ActuNews
13.01.2025
OXUR
LISTED
EURONEXT
OXURION : Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
News Preview
Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential ma...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer
News Preview
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
ZEAL
LISTED
CPH
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
News Preview
Company announcement – No. 1 / 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
AFX
LISTED
XETR
ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow
News Preview
The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE pro, extending ZEISS' LVC market leadership with treatment for myopia, hyperopia, and mixed astigmatism.
DUBLIN, Calif. and JENA, Germany, Jan. 13, 2025 /CNW/ -- ZEISS Medical Technology announced today that the MEL® 90 received approval from the U.S. Food and Drug Administratio...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
TEM
LISTED
NASDAQ
Tempus Announces Preliminary Fourth Quarter and Full Year 2024 Results
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024.
Full Year 2024 Select, Preliminary, Unaudited Financial Results
Revenue of approximately $693 millio...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
SLP
LISTED
NASDAQ
Simulations Plus Supported Development of Every FDA-Approved Drug in 2024
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today highlighted its impact on the pharmaceutical industry through supporting the development of 100% of the drugs approve...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
HELP
LISTED
NASDAQ
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to provide a year-end summary of its key accomplishments in 2024 and upcoming milestones for 2...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.01.2025
EUZ
LISTED
XETR
Eckert & Ziegler und GlyTherix erweitern Zusammenarbeit mit Liefervertrag für Actinium-225
News Preview
Berlin, Deutschland und Sydney, Australien, 13. Januar 2025. Eckert & Ziegler (ISIN DE0005659700, SDAX) und GlyTherix Ltd (GlyTherix), ein australisches Unternehmen für zielgerichtete Strahlentherapie, das auf die Entwicklung von Antikörper-Radiopharmaka zur Behandlung von soliden Tumoren spezialisiert ist, gaben heute die Erweiterung ihrer bes......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.01.2025
EUZ
LISTED
XETR
Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
News Preview
Berlin, Germany and Sydney, Australia, 13. January 2025. Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today announced the expansion of their existing Lutetium-177 based collaboration with a global s......
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
ORNBV
LISTED
HEL
79,345 Orion Corporation A shares converted into B shares
News Preview
ORION CORPORATIONSTOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE13 JANUARY 2025 at 9.50 EET ...
Themefolio
Profiler
Peergroup
© EQS Newswire
13.01.2025
FYB
LISTED
XETR
Teva wird strategischer Vermarktungspartner für Formycons Biosimilar-Kandidat FYB203 (Eylea®/ Aflibercept) in weiten Teilen Europas und Israel
News Preview
Pressemitteilung // 13. Januar 2025
Teva wird strategischer Vermarktungspartner für Formycons Biosimilar-Kandidat FYB203 (Eylea®/ Aflibercept) in weiten Teilen Europas und Israel
Planegg-Martinsried – Die Klinge Biopharma GmbH (Klinge), Lizenznehmer und exklusiver Inhaber der weltweiten Vermarktungsrechte für FYB203, Formycons Biosimilar-Kand......
Themefolio
Profiler
Peergroup
© EQS Newswire
13.01.2025
FYB
LISTED
XETR
Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
News Preview
Presse Release // January 13, 2025
Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
Planegg-Martinsried, Germany – Klinge Biopharma GmbH (Klinge), the licensee and exclusive global commercialization rights holder for FYB203, Formycon’s biosimila......
Themefolio
Profiler
Peergroup
© Globe Newswire
12.01.2025
ASND
LISTED
NASDAQ
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
- Ascendis positioned to drive rapid revenue growth...
Themefolio
Profiler
Peergroup
© PR Newswire
10.01.2025
TRAW
LISTED
NASDAQ
Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program
News Preview
SAN DIEGO, Jan. 10, 2025 /PRNewswire/ -- Expert Systems, a hybrid AI enabled drug discovery and development accelerator, announced a significant milestone in a development of Traws Pharma, Inc. 's (NASDAQ: TRAW) H5N1 antiviral program. The investigational drug, Tivoxavir Marboxil, has shown encouraging results as a single-dose treatment for H5N...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.01.2025
IBAB
LISTED
EURONEXT
Ensuring the continuity of IBA's Entrepreneurial Anchoring
News Preview
Confirmation of the sale of IBA shares to Management Anchorage...
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2025
ZLAB
LISTED
NASDAQ
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
News Preview
Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a rec...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.01.2025
ORY
LISTED
BME
ORYZON to Provide Corporate Progress Updates at Several Events in January-February
News Preview
MADRID and CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several internation...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.01.2025
IMCR
LISTED
NASDAQ
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.01.2025
CHEMM
LISTED
CPH
Upgrade of revenue and operating profit guidance
News Preview
ANNOUNCEMENT NO. 286...
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) to use MediLink’s TMALIN® antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab.
Th...
Themefolio
Profiler
Peergroup
© BusinessWire
09.01.2025
HELP
LISTED
NASDAQ
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a firesid...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.01.2025
MURA
LISTED
NASDAQ
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
News Preview
Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma...
Themefolio
Profiler
Peergroup
© ActuNews
09.01.2025
ALTHX
LISTED
EURONEXT
THERANEXUS ANNOUNCES THE PUBLICATION OF ITS LETTER TO SHAREHOLDERS
News Preview
Lyon, France – January 9, 2025, 6:00 PM CET - Theranexus, an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces the publication of its letter to shareholders.
To download the newsletter, click here.
This letter is also available on the Theranexus website (link), in the Shareholders/Financial D...
Themefolio
Profiler
Peergroup
© ActuNews
09.01.2025
ALTHX
LISTED
EURONEXT
THERANEXUS ANNONCE LA PUBLICATION DE SA LETTRE AUX ACTIONNAIRES
News Preview
Lyon, France – 9 janvier 2025, 18h00 CET - Theranexus, société biopharmaceutique innovante dans le traitement des maladies neurologiques rares, annonce ce jour la publication de sa lettre aux actionnaires.
Pour télécharger la newsletter, cliquez ici.
Cette lettre est également consultable sur le site interne...
Themefolio
Profiler
Peergroup
© EQS Newswire
09.01.2025
FYB
LISTED
XETR
Formycon included in TecDAX Index of Deutsche Börse
News Preview
Press Release // January 9, 2025
Formycon included in TecDAX Index of Deutsche Börse
Formycon to join the ranks of the 30 leading listed technology companies
Uplisting to the Prime Standard, inclusion in the SDAX, and robust business development further enhance the stock’s appeal
Entry into the TecDAX becomes effective as of January 13, 2025
......
Themefolio
Profiler
Peergroup
© EQS Newswire
09.01.2025
FYB
LISTED
XETR
Formycon wird in den TecDAX der Deutschen Börse aufgenommen
News Preview
Pressemitteilung // 09. Januar 2025
Formycon wird in den TecDAX der Deutschen Börse aufgenommen
Formycon gehört künftig zu den 30 gelisteten Top-Technologiewerten
Uplisting in den Prime Standard, Aufstieg in den SDAX und erfolgreiche Geschäftsentwicklung fördern die Attraktivität der Aktie
Aufnahme in den TecDAX ab 13. Januar 2025 wirksam
Pla......
Themefolio
Profiler
Peergroup
© Globe Newswire
09.01.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company AnaCardio raises SEK 205 million and reports positive Phase 1b data of AC01
News Preview
STOCKHOLM, SWEDEN January 9, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has secured SEK 205 million in a series A extension financing round and reports positive results from the first part of a Phase 1b/2a study of AC01 in patients with heart failure and reduced ejection fraction. T...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.01.2025
BAVA
LISTED
CPH
Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million
News Preview
COPENHAGEN, Denmark, January 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a share buy-back program of up to DKK 150 million as announced on December 11, 2024. The decision to launch the program is driven by a better-than-expected performance and improved visibility pertaining to the Company’s Travel Health business, w...
Themefolio
Profiler
Peergroup
© Newsfile
09.01.2025
COPN
LISTED
SIX
Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates
News Preview
Ad hoc announcement pursuant to Art. 53 LR Revenue Growth: Full-year 2024 revenue of €265.7 million (unaudited), marking a 186% increase compared to 2023. Financial Strength: Year-end cash and short-term investments of €170.4 million, reflecting a robust balance sheet with zero debt....
Themefolio
Profiler
Peergroup
© EQS Newswire
09.01.2025
SOON
LISTED
SIX
Sonova gibt personelle Veränderungen im Verwaltungsrat bekannt
News Preview
Sonova Holding AG
/ Schlagwort(e): Personalie
Sonova gibt personelle Veränderungen im Verwaltungsrat bekannt
09.01.2025 / 06:59 CET/CEST
Group Media & Investor Release
Der Verwaltungsrat hat Laura Stoltenberg als neues Mitglied für die Wahl an der nächsten ordentlichen Generalversammlung (GV) im Juni 2025 nominiert.......
Themefolio
Profiler
Peergroup
© EQS Newswire
09.01.2025
SOON
LISTED
SIX
Sonova announces changes to its Board of Directors
News Preview
Sonova Holding AG
/ Key word(s): Personnel
Sonova announces changes to its Board of Directors
09.01.2025 / 06:59 CET/CEST
Group Media & Investor Release
The Board of Directors (the Board) has nominated Laura Stoltenberg for election as a new member at the upcoming Annual General Meeting (AGM) in June 2025. She succe......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.01.2025
FYB
LISTED
XETR
Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
News Preview
Press Release // January 8, 2025
Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
Otulfi® approved by Health Canada for both subcutaneous and intravenous formulations to treat serious inflammatory diseases
Health Canada joins the FDA and the European Commission in gra......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.01.2025
FYB
LISTED
XETR
Formycon und Fresenius Kabi Canada erhalten Zulassung von Health Canada für FYB202/Otulfi® (Ustekinumab), ein Biosimilar zu Stelara®
News Preview
Pressemitteilung // 08. Januar 2025
Formycon und Fresenius Kabi Canada erhalten Zulassung von Health Canada für FYB202/Otulfi® (Ustekinumab), ein Biosimilar zu Stelara®
Otulfi® wurde von Health Canada für subkutane und intravenöse Formulierungen zur Behandlung schwerer entzündlicher Erkrankungen zugelassen
Health Canada schließt sich der FDA un......
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
IMMNOV
LISTED
STO
Immunovia AB (Publ) presents Nomination Committee
News Preview
LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.
According to the instructions for the Nomination Committee of Immunovia AB (Publ), the Nomination Committee shall consist of four members, of which thr...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
IMMNOV
LISTED
STO
Immunovia AB (Publ) presents Nomination Committee
News Preview
LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.
According to the instructions for the Nomination Committee of Immunovia AB (Publ), the Nomination Committee shall consist of four members, of which thr...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2025
ICLR
LISTED
NASDAQ
Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for A...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2025
GLPG
LISTED
EURONEXT
Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities
News Preview
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions...
Themefolio
Profiler
Peergroup
© BusinessWire
08.01.2025
POAI
LISTED
NASDAQ
PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Predictive Oncology Inc. (NasdaqCM: POAI) to Renovaro Inc. (NasdaqCM: RENB). Under the terms of the binding letter of intent, Predictive Oncology will be merged into Renovaro in exchange for...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
